PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10773217-3 2000 We now report that an irreversible AChE inhibitor (metrifonate) increase the cell-associated APP level in a basal forebrain neuronal culture and also elevate the amount of APP secreted into the medium. Trichlorfon 51-62 acetylcholinesterase (Cartwright blood group) Homo sapiens 35-39 18825528-3 2009 The presented study is aimed at reactivation of trichlorfon-inhibited butyrylcholinesterase since this enzyme play an important role in Alzheimer"s disease as deputy for acetylcholinesterase and furthermore it could be applied as a scavenger in case of overdosing. Trichlorfon 48-59 acetylcholinesterase (Cartwright blood group) Homo sapiens 170-190 18804659-8 2008 The most significant identification was based on methamidophos inhibited AChE reactivation by HI-6 or pralidoxime and paraoxon-ethyl inhibited AChE by obidoxime; moreover, identification of trichlorfon and paraoxon-methyl was possible, too. Trichlorfon 190-201 acetylcholinesterase (Cartwright blood group) Homo sapiens 143-147 18049927-4 2007 This enzyme is more sensitive than AChE to some organophosphates (OP), including dichlorvos, which is the parent compound for metrifonate, a therapeutic agent used in the treatment of cognitive impairment associated to Alzheimer"s disease. Trichlorfon 126-137 acetylcholinesterase (Cartwright blood group) Homo sapiens 35-39 14535624-6 2003 Among these inhibitors, tacrine, bis-tacrine, TAK-147, metrifonate and galantamine inhibited both the G1 and G4 AChE forms equally well. Trichlorfon 55-66 acetylcholinesterase (Cartwright blood group) Homo sapiens 112-116 27939611-6 2017 At high concentration (1mM), trichlorfon induced effects similar to those of the neuropathic OP, mipafox (20muM), but also caused high inhibition of AChE. Trichlorfon 29-40 acetylcholinesterase (Cartwright blood group) Homo sapiens 149-153 25596135-6 2015 Trichlorfon and mipafox presented the lowest percentage of reactivation of inhibited NTE and the lowest ratio IC50 NTE/IC50 AChE. Trichlorfon 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 124-128 10718203-5 2000 Metrifonate produced a mean erythrocyte acetylcholinesterase inhibition at the end of treatment of 86.3%. Trichlorfon 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-60 10718203-13 2000 This metrifonate dose provided a high level of acetylcholinesterase inhibition, which was associated in these patients with a favorable safety and tolerability profile. Trichlorfon 5-16 acetylcholinesterase (Cartwright blood group) Homo sapiens 47-67 10791297-0 2000 The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer"s disease patients after treatment with metrifonate. Trichlorfon 119-130 acetylcholinesterase (Cartwright blood group) Homo sapiens 36-56 10365643-0 1999 Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor metrifonate in patients with renal impairment. Trichlorfon 76-87 acetylcholinesterase (Cartwright blood group) Homo sapiens 45-65 10622674-8 1999 A number of preliminary studies, whose results are summarized here, have demonstrated that the use of the acetylcholinesterase inhibitors tacrine, metrifonate and donepezil, and the glial cell modulator, propentofylline, results in reductions in the overall costs of care. Trichlorfon 147-158 acetylcholinesterase (Cartwright blood group) Homo sapiens 106-126 10365643-1 1999 The aim of this study was to assess the influence of renal function on the pharmacokinetics, pharmacodynamics, safety, and tolerability of the acetylcholinesterase inhibitor metrifonate. Trichlorfon 174-185 acetylcholinesterase (Cartwright blood group) Homo sapiens 143-163 15616667-3 1998 Currently used AChE inhibitors are tacrine, donepezil hydrochloride, rivastigmine and metrifonate. Trichlorfon 86-97 acetylcholinesterase (Cartwright blood group) Homo sapiens 15-19 9924498-6 1999 Augmentation of cholinergic function through the use of acetylcholinesterase inhibitors with favorable side-effect profiles (e.g., donepezil, possibly metrifonate) can create the potential for improved memory and cognition. Trichlorfon 151-162 acetylcholinesterase (Cartwright blood group) Homo sapiens 56-76 9758325-1 1998 Seizures occurred in two patients with probable Alzheimer"s disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor. Trichlorfon 112-123 acetylcholinesterase (Cartwright blood group) Homo sapiens 141-161 10363493-10 1999 Metriphonate is a prodrug of short life which inhibits acetylcholinesterase through a metabolite (DDVP) with a half-life in the circulation of 2 h. Improvement is observed in the ADAS-Cog scale and the CIBIC-Plus and in behavior disorders at doses of 0.3 and 0.65 mg/kg/day. Trichlorfon 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 55-75 10363493-12 1999 CONCLUSIONS: Different studies carried out with the acetylcholinesterase inhibitors donepezil, rivastigmine and metriphonate have been effective in the control of the cognitive symptoms of Alzheimer disease in the initial or moderate phases of the disease. Trichlorfon 112-124 acetylcholinesterase (Cartwright blood group) Homo sapiens 52-72 9758555-1 1998 Irreversible AChE inhibition with metrifonate]. Trichlorfon 34-45 acetylcholinesterase (Cartwright blood group) Homo sapiens 13-17 9718228-1 1998 The promising results of early trials in Alzheimer"s disease with the acetylcholinesterase inhibitor metrifonate prompted initiation of the Metrifonate in ALzheimer"s Trial (MALT). Trichlorfon 101-112 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-90 9549662-1 1998 Metrifonate is converted nonenzymatically to 2.2, dimethyl dichlorovinyl phosphate (DDVP), an inhibitor of acetylcholinesterase (AChE). Trichlorfon 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 107-127 9549662-1 1998 Metrifonate is converted nonenzymatically to 2.2, dimethyl dichlorovinyl phosphate (DDVP), an inhibitor of acetylcholinesterase (AChE). Trichlorfon 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 129-133 9718228-1 1998 The promising results of early trials in Alzheimer"s disease with the acetylcholinesterase inhibitor metrifonate prompted initiation of the Metrifonate in ALzheimer"s Trial (MALT). Trichlorfon 140-151 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-90 9718229-2 1998 A double-blind, placebo-controlled, 26-week study of the AChE inhibitor metrifonate using the NeuroPsychiatric Inventory (NPI) to assess the effects of treatment on neuropsychiatric symptoms observed statistically significant mean change differences favouring treatment in the total NPI score and in symptoms of depression, apathy and hallucinations, as well as a nearly significant difference in aberrant motor behaviours. Trichlorfon 72-83 acetylcholinesterase (Cartwright blood group) Homo sapiens 57-61 9720485-1 1998 Metrifonate, administered orally to patients with probable Alzheimer"s disease in a once-daily dose, readily enters the brain and inhibits brain acetylcholinesterase (AChE) activity in a dose-dependent fashion. Trichlorfon 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 145-165 9720485-2 1998 Metrifonate is a prodrug, converted non-enzymatically to 2,2-dichlorovinyl dimethyl phosphate, a long-acting inhibitor of AChE that produces stable enzyme inhibition over time. Trichlorfon 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 122-126 9720485-1 1998 Metrifonate, administered orally to patients with probable Alzheimer"s disease in a once-daily dose, readily enters the brain and inhibits brain acetylcholinesterase (AChE) activity in a dose-dependent fashion. Trichlorfon 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 167-171 9585171-1 1998 Metrifonate, a pro-drug that is transformed non-enzymatically into a potent inhibitor of acetylcholinesterase (AChE), has been used in the tropics for over 30 years for the treatment of schistosomiasis. Trichlorfon 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 111-115 9585171-1 1998 Metrifonate, a pro-drug that is transformed non-enzymatically into a potent inhibitor of acetylcholinesterase (AChE), has been used in the tropics for over 30 years for the treatment of schistosomiasis. Trichlorfon 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 89-109 9585171-2 1998 A pilot study, and Phase I and Phase II studies of metrifonate in Alzheimer"s disease (AD) patients conducted prior to the current study showed benign, dose-dependent adverse event profiles consisting primarily of gastrointestinal events, optimal daily dosing with a loading phase (in the absence of a loading dose phase, 6-8 weeks were required to attain steady-state AChE inhibition levels), and an improvement in Alzheimer"s Disease Assessment Scale (ADAS) scores. Trichlorfon 51-62 acetylcholinesterase (Cartwright blood group) Homo sapiens 369-373 8876775-0 1996 Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Trichlorfon 42-53 acetylcholinesterase (Cartwright blood group) Homo sapiens 58-78 9268605-4 1997 Inhibition of AChE was greater than inhibition of NTE, without overlap of the concentration-response curves, for OPs which are more likely to cause acute, rather than delayed, neurotoxic effects in vivo (e.g., chlorpyrifos-oxon, dichlorvos, and trichlorfon). Trichlorfon 245-256 acetylcholinesterase (Cartwright blood group) Homo sapiens 14-18 8876775-2 1996 We dosed metrifonate to achieve a 40-60% inhibition of red blood cell acetylcholinesterase activity. Trichlorfon 9-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-90 8783813-3 1996 For this purpose human erythrocyte AChE (EC 3.1.1.7) was inhibited (30 min) by chlorfenvinphos, dichlorvos, dicrotophos, heptenophos, mevinphos, monocrotophos, paraoxon, phosphamidon, trichlorfon, malaoxon, omethoate, oxydemeton-methyl or methamidophos by 85-98% of control. Trichlorfon 184-195 acetylcholinesterase (Cartwright blood group) Homo sapiens 35-39 1858789-3 1991 We recently treated 18 Alzheimer disease patients with metrifonate, a long-acting AChE inhibitor, over periods up to 7 months, with resulting erythrocyte AChE inhibition as high as 82 per cent of baseline values. Trichlorfon 55-66 acetylcholinesterase (Cartwright blood group) Homo sapiens 82-86 7636741-5 1995 The purpose of this study was to determine the selectivity of physostigmine, metrifonate, methanesulfonyl fluoride and tetrahydroaminoacridine (tacrine) toward AChE as compared with butyrylcholinesterase (BChE) in human cortex. Trichlorfon 77-88 acetylcholinesterase (Cartwright blood group) Homo sapiens 160-164 7636741-8 1995 Metrifonate was found to inhibit BChE more than AChE. Trichlorfon 0-11 acetylcholinesterase (Cartwright blood group) Homo sapiens 48-52 1858789-3 1991 We recently treated 18 Alzheimer disease patients with metrifonate, a long-acting AChE inhibitor, over periods up to 7 months, with resulting erythrocyte AChE inhibition as high as 82 per cent of baseline values. Trichlorfon 55-66 acetylcholinesterase (Cartwright blood group) Homo sapiens 154-158 235931-0 1975 Mechanism of inhibition in vitro of mammalian acetylcholinesterase and cholinesterase in solutions of 0,0-dimethyl 2,2,2-trichloro-1-hydroxyethyl phosphonate (Trichlorphon). Trichlorfon 159-171 acetylcholinesterase (Cartwright blood group) Homo sapiens 46-66